CD34 and triple-A syndrome: We observed limited CD31/CD34 positivity as a hallmark of reduced angiogenesis in all lenvatinib-treated animals, as well as reduced expression of VEGFR2 in human AAA patient-derived primary cells (Figure 1E, Figure 2D, Figure 3B, and Figure 4B).